Erbitux utilization (correction)
First-line colorectal cancer penetration for Bristol-Myers Squibb/ImClone's Erbitux (cetuximab) was 4% in the fourth quarter of 2005. Second- and third-line penetration was 13% and 31%, respectively, ImClone said. Among the total number of patients using Erbitux, 82% were being treated for colorectal cancer. In a Jan. 30 story, "The Pink Sheet" (p. 14) incorrectly characterized Erbitux usage in the overall colorectal cancer population...
You may also be interested in...
There could be 28 notified body designations in total under the Medical Device Regulation by the end of 2021. But there is cause for concern over designations under the IVD Regulation, which are lagging far behind.
Swiss Health Providers Turn Heat On Federal Council: 12% Loss Of Medtech Products Likely On EU MRA Failure
A consortium of Swiss providers, patient groups and health care trade bodies is imploring the federal council to avert a looming patient care crisis in Switzerland if the EU MRA cannot be agreed.
China’s first domestically-developed recombinant protein vaccine for COVID-19 moves forward in late-stage trials in two countries.